Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone

Marcos Gómez-Revuelta, José María Pelayo-Terán, María Juncal-Ruiz, Víctor Ortiz-García de la Foz, Javier Vázquez-Bourgon, Ana González-Pinto, Benedicto Crespo-Facorro

University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain (Dr Gómez-Revuelta, Dr Pelayo-Terán, Dr Juncal-Ruiz, Mr Ortiz-García de la Foz, Dr Vázquez-Bourgon, Dr Crespo-Facorro); CIBERSAM, Centro Investigación Biomédica en Red Salud Mental, Madrid, Spain (Dr Gómez-Revuelta, Dr Pelayo-Terán, Dr Juncal-Ruiz, Mr Ortiz-García de la Foz, Dr Vázquez-Bourgon, Dr González-Pinto, Dr Crespo-Facorro); Unidad de Gestión Clínica de Psiquiatría y Salud Mental, Hospital El Bierzo, Servicio de Salud de Castilla y León, Ponferrada (León), Spain (Dr Pelayo-Terán); Hospital Universitario de Álava, Osakidetza, Department of Psychiatry, UPV-EHU, Vitoria-Gasteiz, Spain (Dr González-Pinto).

Correspondence: José María Pelayo Terán, MD, PhD, University Hospital Marqués de Valdecilla-IDIVAL CIBERSAM, Department of Psychiatry, School of Medicine, University of Cantabria, Santander, Spain; Avda, Valdecilla, s/n. | 39008 Santander, Cantabria, Spain (pelayoteran@gmail.com).

Abstract

Background: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up.

Method: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy.

Results: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole = 73.08%, ziprasidone = 79.03%, and quetiapine = 95.16%) (χ² = 11.680; P = .001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank = 32.260; P = .001). Significant differences between treatments were found in the categories of sleepiness/sedation (χ² = 9.617; P = .008) and increased sleep duration (χ² = 6.192; P = .004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines.
Conclusions: First‐episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.

Keywords: antipsychotic agents, schizophrenia, first‐episode psychosis, effectiveness
de Valdecilla, Spain (Pelayo-Terán et al., 2008). Conforming to international standards for research ethics, this program was approved by the local institutional review board. Patients meeting inclusion criteria and their families provided written informed consent prior to their inclusion in the program.

Subjects

From October 2005 to January 2011, all referrals to PAFIP were screened for patients who met the following criteria: (1) 15 to 60 years; (2) living in the catchment area; (3) experiencing their FEP; (4) no prior treatment with antipsychotic medication or, if previously treated, a lifetime total duration of antipsychotic treatment of <6 weeks; and (5) DSM-IV criteria for brief psychotic disorder, schizophrenia, or schizoaffective disorder. Patients were excluded for any of the following reasons: (1) meeting DSM-IV criteria for drug dependence, (2) meeting DSM-IV criteria for mental retardation, or (3) having a history of neurological disease or head injury. The diagnoses were confirmed using the Structured Clinical Interview for DSM-IV (First et al., 2002) carried out by an experienced psychiatrist 6 months after the baseline visit. Our operational definition for an FEP included individuals with a nonaffective psychosis (meeting the inclusion criteria defined above) who had not received previous antipsychotic treatment regardless of the duration of psychosis.

Study Design

This was a prospective, randomized, flexible dose, open-label study. We used a simple randomization procedure. An automated randomization list was drawn up. At study intake, all patients but 8 were antipsychotic naïve. Before starting on the assigned drug, these subjects underwent a 2- to 4-day washout period. Mean antipsychotic doses expressed as chlorpromazine equivalents (mg/d) (Woods, 2003) were as follow: quetiapine 100 to 600 mg/d (133.33–800 mg/d of chlorpromazine), ziprasidone 40 to 160 mg/d (66.67–266.67 mg/d of chlorpromazine), and aripiprazole 5 to 30 mg/d (66.67–400 mg/d of chlorpromazine). A rapid titration schedule (5 days), until optimal dose was reached, was used as a rule unless severe side effects occurred. At the treating psychiatrist's discretion, the dose and type of antipsychotic medication could be changed based on clinical efficacy and the profile of side effects during the follow-up period. Anticholinergic medications, lorazepam, were permitted for clinical reasons. No anticholinergic agents were administered prophylactically. Antidepressants and mood stabilizers were permitted if clinically needed. The severity scale of the Clinical Global Impression (CGI) scale (Guy, 1976), the Brief Psychiatric Rating Scale (BPRS) (expanded version of 24 items) (Overall and Gorham, 1962), the Scale for the Assessment of Positive symptoms (SAPS) (Andreasen, 1984), the Scale for the Assessment of Negative symptoms (SANS) (Andreasen, 1989), the Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al., 1993), and the Young Mania Rating Scale (YMRS) (Young et al., 1978) were used to evaluate clinical symptomsatology. The scale of the Udvalg for Kliniske Undersogelser (Committee of Clinical Trials) (Lingjaerde et al., 1987), the Simpson-Angus Rating Scale (SARS) (Simpson and Angus, 1970) and the Barnes Akathisia Scale (BAS) (Barnes, 1989) were used to assess side effects. Clinical assessments and measurements were completed at baseline, at 3 weeks, at 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, and 36 months. All patients included in the analysis had at least the baseline and 3-year assessments and were considered for drop-out in those cases in which they did not attend 2 consecutive check-point assessments. The same trained psychiatrist (B.C.-F.) completed all clinical assessments.

Outcome Measures

Primary Outcome Measures: Effectiveness

The main outcome of effectiveness was the treatment discontinuation rate, which is the percentage of all-cause discontinuation of the initially assigned treatment (patients who completed the 3-year follow-up assessment and changed their initial antipsychotic) and the mean time to all-cause medication discontinuation (two accepted indexes of medication effectiveness). Four reasons for the discontinuation were recorded: (1) nonefficacy or insufficient efficacy, (2) significant side effects, (3) nonadherence, and (4) other causes.

Insufficient efficacy was established at the treating physician's judgment only after at least 3 weeks of treatment. Adherence to antipsychotic drugs was assessed by information obtained from patients, close relatives, and the staff (nurses, social workers, and psychiatrists) involved in the follow-up. For the present investigation, patients were consensually dichotomized into having a good (defined as patients regularly taking at least 90% of prescribed medication) and a poor adherence (medium or poor compliance). If more than one reason for discontinuation was present, the most important reason according to the above ranking was selected.

Secondary Outcome Measures: Efficacy and Safety

The efficacy outcomes were the mean change from baseline to 3 years in BPRS, SAPS, and SANS total scores. Additional analyses included changes from baseline to 3 years in CGI, YMRS, and CDSS total scores. Patients were defined as responders to the optimum dose of antipsychotic if they had a ≥50% reduction of BPRS total score and a CGI severity score ≤4 after 6 months since the beginning of the treatment. Side effects were evaluated using the Udvalg for Kliniske Undersogelser side effect rating scale. Those treatment-emergent side effects that occurred at a rate of at least 5% in either treatment group at any time during the follow-up period were considered. Only those side effects rated as severe moderate or severe and with a possible causal relationship to medication were recorded. Treatment-emergent akathisia and extrapyramidal symptoms were assessed using BAS and SARS scales, respectively. Treatment-emergent parkinsonism was defined as a total score >3 on the SARS at any of the check-point assessments, given a total score of ≤3 at baseline.

Statistical Analyses

All data were tested for normality (Kolmogorov-Smirnov test) and equality of variances (Levene test). To ensure group comparability, baseline sociodemographic and clinical characteristics were tested by 1-way ANOVA or Kruskal-Wallis test for continuous variables as necessary or by chi-squared test for qualitative variables.

Kaplan-Meier survival curves and a log-rank test were used to assess time to all-cause medication discontinuation. Concerning these 2 analyses, patients were followed-up from the inclusion in the study until discontinuation of the initial treatment or censoring. Survival time could be censored by the end
of the observation period or by loss to follow-up (patients who dropped out before discontinuation of the initial treatment).

For efficacy and safety measures related to side effects, this research adopted an intention-to-treat analysis paradigm, and patients were followed-up for at least 3 years after their inclusion regardless of whether they had switched their randomly assigned treatment, with the exception of those patients who dropped out of the study and were thus unable to complete the follow-up. In addition, per protocol analyses were performed and are available upon request.

Differences between groups in the degree of change in clinical scores from baseline were evaluated with ANCOVA after baseline scores were controlled. Finally, comparisons of the discontinuation rates and the prevalence of side effects as well as the use of concomitant treatment between the 3 antipsychotics were carried out, performing chi-square tests with Bonferroni correction for multiple comparisons when necessary.

STATA 15.0 was used for statistical analysis. Statistical tests were 2-tailed with a 95% CI.

Results

Of 224 individuals initially randomized to treatments, 22 were finally removed from the dataset because it was verified they did not fully meet inclusion criteria or removed proper written consent during the first week. Thus, the final sample consisted of 202 subjects: 78 patients were randomly assigned to the aripiprazole group, and 62 patients were randomly assigned to both the quetiapine and ziprasidone groups (Figure 1). At baseline, only 8 (4.0%) patients reported some prior antipsychotic treatment. The mean self-reported duration of prior treatment was 1.5 weeks (SD = 1.3; range, 0.4–4.0). The overall dropout rate at 3 years was small (n = 39; 19.3%: 12 aripiprazole, 10 ziprasidone, and 17 quetiapine). A total 22 patients dropped out of the follow-up prior to treatment discontinuation and were censored for the survival analysis (9 aripiprazole, 8 quetiapine, and 5 ziprasidone). Four patients committed suicide during the 3-year follow-up (1 aripiprazole, 1 ziprasidone, and 2 quetiapine) and there was one sudden death (aripiprazole; heart attack). All but 10 individuals were white Caucasian. Demographic and clinical characteristics of patients are shown in Table 1.

Primary Outcome Measures

Treatment Discontinuation Rate and Time to Discontinuation
The all-cause treatment discontinuation rate differed significantly between treatment groups (χ² = 11.680; P = .001) (Table 2). Patients on quetiapine showed a higher (95.16%) treatment discontinuation rate than patients taking aripiprazole (73.08%) or ziprasidone (79.03%). The time (days) until approximately 50% of the patients left their initial treatment due to any cause was 452 days for aripiprazole, 251 days for ziprasidone, and 60 days for quetiapine. There was a significant difference between groups in median time to discontinuation.
(log rank = 32.260; P = .001) (Figure 2). Log-rank pairwise comparisons between treatment groups showed the following results: aripiprazole vs quetiapine ($\chi^2 = 28.95; P = .000$), ziprasidone vs quetiapine ($\chi^2 = 14.29; P = .000$), and aripiprazole vs ziprasidone ($\chi^2 = 2.02; P = .156$). Consequently, we found statistically significant differences between aripiprazole and quetiapine and between ziprasidone and quetiapine but not between aripiprazole and ziprasidone, where we only found a trend towards nondiscontinuation favoring aripiprazole. Nonefficacy or insufficient efficacy in the quetiapine group was the main reason for discontinuation rate differences ($\chi^2 = 22.694; P = .000$). Patients under quetiapine treatment were significantly more likely to discontinue due to nonefficacy or insufficient efficacy compared with aripiprazole ($\chi^2 = 19.450; P = .000$) or ziprasidone patients ($\chi^2 = 11.414; P = .000$). No significant differences were found between the aripiprazole and ziprasidone groups in terms of nonefficacy or insufficient efficacy ($\chi^2 = 0.734; P = 1.0$). Mean (SD) doses prior to discontinuation due to nonefficacy or insufficient efficacy were: aripiprazole, 15.7 mg (8.6); ziprasidone,
Analysis of treatment discontinuation because of side effects showed significant differences between treatment groups (quetiapine 12.9%, ziprasidone 37.1%, and aripiprazole 12.82%; \( \chi^2 = 15.607; P = .000 \)). Patients initially treated with ziprasidone discontinued treatment significantly more frequently than those on aripiprazole (\( \chi^2 = 11.300; P = .002 \)) or quetiapine (\( \chi^2 = 9.677; P = .006 \)) due to side effects. Regarding the direct comparison between quetiapine and aripiprazole, no significant differences were found (\( \chi^2 = 0.000; P = 1.0 \)). Finally, there is a remarkable difference in terms of treatment adherence. After intention-to-treat analysis, individuals in the aripiprazole group showed worse compliance than those in the ziprasidone group (\( \chi^2 = 8.792; P = .012 \)); however, no differences were found between the aripiprazole and quetiapine groups (\( \chi^2 = 3.413; P = .194 \)) or between the ziprasidone and quetiapine groups (\( \chi^2 = 0.954; P = .986 \)). In those patients who continued taking the initial prescribed drug, mean antipsychotic doses at 3 years, adjusted in chlorpromazine equivalents, were aripiprazole, 216.8 (SD = 164.1) mg/d; ziprasidone, 202.2 (SD = 136.5) mg/d; and quetiapine, 261.1 (SD = 136.5) mg/d, with no significant differences observed (\( P = .279 \)) between treatment groups.

### Secondary Outcome Measures

#### Clinical Efficacy

Intention-to-treat analyses showed that there were no statistically significant differences between treatment groups in the severity of symptoms at baseline and at 3 years except for BPRS (\( P = .043 \)) and CGI (\( P = .040 \)) at baseline (Table 3). Posthoc analyses with Bonferroni correction found statistically significant differences between aripiprazole and ziprasidone in the BPRS (\( P = .030 \)) and CGI scales (\( P = .035 \)) at baseline. ANCOVA analyses showed no changes in the differences of the total scores of the clinical scales between treatments (all \( P > .1 \)) after controlling by baseline measurements except for the CDSS (\( P = .026 \)); Bonferroni correction was significant for the comparison between aripiprazole and quetiapine for the CDSS (\( P = .030 \)).

The rate of responders was also similar between aripiprazole, ziprasidone, and quetiapine (56.28%, 52.84%, 52.11%, respectively; \( F = 1.25; P = .293 \)). All treatments decreased at least 4 points on the CGI scale from baseline to 3 years (Table 3). Statistically significant differences between treatments were not found (\( F = 0.41; P = .664 \)).

#### Safety

### Adverse Events

Intention-to-treat analyses of moderate and severe side effects that were frequent (in at least 5% of patients in any of the treatment groups) are displayed in Table 4. Significant differences between treatments were found in the categories of sleepiness/sedation (\( \chi^2 = 9.617; P = .008 \)) and increased sleep duration (\( \chi^2 = 6.192; P = .040 \)). After adjustment by Bonferroni correction, statistically significant differences were only found when comparing aripiprazole and quetiapine for sleepiness/sedation (\( P = .007 \)) and increased sleep duration (\( P = .05 \)). No significant differences between treatments were found after performing per-protocol analysis (data available upon request).

### Extrapyramidal Symptoms

Intention-to-treat analyses have shown no significant differences in the increment of extrapyramidal signs at 3 years (SARS total score) between treatments (\( F = .132; P = .936 \)). The percentage of patients with treatment-emergent extrapyramidal symptoms (EPS) was not statistically different between treatment arms (aripiprazole = 17.8%; ziprasidone = 17.3%, and quetiapine 15.4%; \( \chi^2 = 0.461; P = .794 \)). Per-protocol analysis showed rather similar results (data available upon request). There was no significant difference between treatments in the severity of akathisia (BAS total score) (\( F = .532; P = .588 \)). Although the difference did not reach a significant level, a higher number of individuals in the aripiprazole (22.6%) and ziprasidone groups (32.7%) experienced treatment-emergent akathisia (BAS global score of 2 or more at check-point evaluations, given a global score of <2 at baseline visit) compared with quetiapine-treated subjects (17.8%) (\( \chi^2 = 3.910; P = .142 \)).

### Concomitant Medication Use

Intention-to-treat analyses showed no significant differences between antipsychotic treatment groups regarding the use of concomitant medication, except for benzodiazepines (\( \chi^2 = 10.76; P = .005 \)). After adjustment by Bonferroni correction, chi-square tests revealed that benzodiazepine use in the aripiprazole group was significantly higher than in the quetiapine group (92.3% vs 72.6%; \( \chi^2 = 9.791; P = .005 \)). However, there were no statistically significant differences in the use of benzodiazepines between the aripiprazole group and the ziprasidone group (92.3% vs 87.1%; \( \chi^2 = 1.042; P = .921 \)) or between the quetiapine group and the ziprasidone group (72.6% vs 87.1%; \( \chi^2 = 4.06; P = .132 \)).

---

**Figure 2. Kaplan-Meyer survival graph: All-cause discontinuation.**

80.4 mg (40.3); and quetiapine, 490 mg (251.1).
In previous studies, aripiprazole and ziprasidone demonstrated significantly higher effectiveness (lower all-cause treatment discontinuation rates and mean time to discontinuation) than quetiapine in the acute treatment of an FEP. This trend was confirmed after a 3-year follow-up. Nonefficacy or insufficient efficacy in the quetiapine group was the main reason for discontinuation rate differences between antipsychotics. The profile of motor side effects varied between treatments, as did the ability of each group to adhere to treatment. These factors may contribute to additional differences in terms of effectiveness. Instead, intention-to-treat analysis revealed no treatment advantages in reducing the severity of symptomatology (efficacy) between the 3 SGAs.

### Table 3. Intention-to-Treat Sample: Psychopathological Characteristics at Baseline and 3 Years and Clinical Changes during the Follow-Up Period

|                | Total sample | Aripiprazole | Quetiapine | Ziprasidone |
|----------------|--------------|--------------|------------|-------------|
|                | n = 163      | n = 66       | n = 45     | n = 52      |
|                | Mean    | SD        | Mean    | SD        | Mean    | SD        | F      | P      |
| SAPS Baseline  | 14.2    | 4.3       | 14.6    | 4.4       | 13.9    | 4.1       | -0.526 | .592   |
| 3 Years        | 1.1     | 2.8       | 1.0     | 2.8       | 1.4     | 3.0       | 0.314  | .731   |
| Changea        | -13.0   | 4.8       | -13.6   | 4.7       | -12.5   | 5.3       | -12.8  | 4.6    |
| Changeb        | -13.2   | 0.3       | -12.7   | 0.4       | -13.1   | 0.4       | 0.876  | .458   |
| SANS Baseline  | 6.7     | 6.1       | 7.5     | 6.8       | 6.3     | 6.0       | 6.1    | 5.4    |
| 3 Years        | 3.6     | 5.4       | 3.9     | 5.7       | 3.8     | 5.8       | 3.1    | 4.8    |
| Changea        | -3.1    | 7.3       | -3.6    | 8.3       | -2.5    | 5.7       | -3.0   | 7.5    |
| Changeb        | -2.9    | 0.7       | -2.8    | 0.8       | -3.5    | 0.7       | 0.384  | .681   |
| BPRS Baseline  | 64.7    | 12.6      | 67.7    | 12.6      | 63.9    | 12.0      | 61.7   | 12.6   |
| 3 Years        | 29.9    | 8.8       | 29.6    | 10.0      | 30.6    | 9.8       | 29.1   | 7.3    |
| Changea        | -34.9   | 13.8      | -38.0   | 15.0      | -33.3   | 13.7      | -32.6  | 12.0   |
| Changeb        | -35.5   | 1.1       | -34.0   | 1.3       | -35.2   | 1.3       | 0.403  | .670   |
| CGI Baseline   | 6.5     | 0.6       | 6.6     | 0.6       | 6.5     | 0.6       | 6.3    | 0.6    |
| 3 Years        | 2.4     | 1.6       | 2.5     | 1.7       | 2.5     | 1.8       | 2.1    | 1.4    |
| Changea        | -4.2    | 1.7       | -4.2    | 1.7       | -4.1    | 1.9       | -4.2   | 1.5    |
| Changeb        | -4.1    | 0.2       | -4.1    | 0.2       | -4.3    | 0.2       | 0.410  | .664   |
| Positive dimension Baseline | 7.5 | 2.4       | 7.6     | 2.6       | 7.6     | 2.4       | 7.3    | 2.3    |
| 3 Years        | 0.7     | 1.7       | 0.5     | 1.8       | 1.0     | 1.9       | 0.5    | 1.3    |
| Changea        | -6.8    | 2.8       | -7.0    | 2.8       | -6.6    | 3.0       | -6.8   | 2.6    |
| Changeb        | -7.0    | 0.2       | -6.5    | 0.2       | -6.9    | 0.2       | 0.410  | .664   |
| Disorganized dimension Baseline | 6.7 | 3.3       | 7.0     | 3.2       | 6.3     | 3.2       | 6.6    | 3.5    |
| 3 Years        | 0.5     | 1.6       | 0.5     | 1.5       | 0.4     | 1.4       | 0.6    | 1.8    |
| Changea        | -6.2    | 3.6       | -6.5    | 3.6       | -5.9    | 3.6       | -6.0   | 3.6    |
| Changeb        | -6.2    | 0.2       | -6.3    | 0.2       | -6.1    | 0.2       | 0.112  | .894   |
| Negative dimension Baseline | 4.5 | 5.4       | 5.0     | 6.0       | 4.3     | 5.4       | 3.9    | 4.7    |
| 3 Years        | 3.2     | 4.9       | 3.5     | 5.1       | 3.3     | 5.1       | 2.8    | 4.4    |
| Changea        | -1.3    | 6.4       | -1.6    | 7.2       | -1.0    | 5.0       | -1.2   | 6.5    |
| Changeb        | -1.1    | 0.6       | -1.1    | 0.7       | -1.6    | 0.7       | 0.182  | .834   |
| YMRS Baseline  | 11.9    | 5.0       | 11.8    | 5.0       | 12.3    | 5.5       | 11.7   | 4.6    |
| 3 Years        | 1.4     | 3.3       | 1.0     | 2.2       | 1.9     | 3.6       | 1.5    | 4.1    |
| Changea        | -10.5   | 5.4       | -10.8   | 5.0       | -10.4   | 6.8       | -10.1  | 4.7    |
| Changeb        | -10.9   | 0.4       | -10.0   | 0.5       | -10.3   | 0.5       | 0.974  | .380   |
| CDSS Baseline  | 2.5     | 3.5       | 2.8     | 3.6       | 2.7     | 3.3       | 2.0    | 3.5    |
| 3 Years        | 0.4     | 1.3       | 0.7     | 1.8       | 0.1     | 0.3       | 0.3    | 0.9    |
| Changea        | -2.1    | 3.7       | -2.1    | 4.1       | -2.6    | 3.3       | -1.8   | 3.5    |
| Changeb        | -1.8    | 0.2       | -2.5    | 0.2       | -2.3    | 0.2       | 0.379  | .026   |

Abbreviations: BPRS, Brief Psychiatric Rating Scale; CDSS, Calgary Depression Rating Scale for Schizophrenia; CGI, Clinical Global Impression; SANS, Scale for the Assessment of Negative Symptoms; SAPS, Scale for the Assessment of Positive Symptoms; YMRS, Young Mania Rating Scale.

*a*3-Year change from baseline.

*b*3-Year change from baseline after controlling for baseline.

### Discussion

In previous studies, aripiprazole and ziprasidone demonstrated significantly higher effectiveness (lower all-cause treatment discontinuation rates and mean time to discontinuation) than quetiapine in the acute treatment of an FEP. This trend was confirmed after a 3-year follow-up. Nonefficacy or insufficient efficacy in the quetiapine group was the main reason for discontinuation rate differences between antipsychotics. The profile of motor side effects varied between treatments, as did the ability of each group to adhere to treatment. These factors may contribute to additional differences in terms of effectiveness. Instead, intention-to-treat analysis revealed no treatment advantages in reducing the severity of symptomatology (efficacy) between the 3 SGAs.
phases of treatment (Ciudad et al., 2008; Crespo-Facorro et al., 2008). Quetiapine patients had already been described during early clinical trials and are considered effective (McEvoy et al., 2007). Our results are consistent with the notion that quetiapine is due to the product itself or to nonoptimal dosage adjustment by chlorpromazine equivalents prior to discontinuation because of nonefficacy or insufficient efficacy. The quetiapine group presented with a higher relative dosage compared with the other groups. According to other reports (Tiihonen et al., 2013) and FGAs (Vanasse et al., 2016). Regarding the latter study, the authors also warned about a higher risk for health events related to quetiapine. Our results are consistent with the notion that most of the patients who start quetiapine stop taking it within a few weeks (Asmal et al., 2013). Inadequate and transient dopamine–2 receptor occupancy has been proposed as a possible mechanism underlying quetiapine lack of efficacy. On the other hand, its weak dopamine antagonism allows low maximal occupancy values and relatively little variability in occupancy values, suggesting that high doses of this antipsychotic are not likely to exceed thresholds of more than 80% occupancy, indicative for D2-receptor-mediated side effects (Lako et al., 2007). We did not find significant differences between groups concerning treatment dosage adjusted by chlorpromazine equivalents prior to discontinuation due to nonefficacy or insufficient efficacy. The quetiapine group presented with a higher relative dosage compared with the other groups. According to other reports (Tiihonen et al., 2013), it is difficult to discern whether the poorer performance of quetiapine is due to the product itself or to nonoptimal dosage. It is of note that ziprasidone and aripiprazole all-cause discontinuations seem to occur later during treatment, likely due to the emergence of side effects (37.1% in ziprasidone group) and nonadherence (33.3% in aripiprazole group), respectively. Actually, most all-cause discontinuations in the ziprasidone sample due to secondary effects (65.2%) took place between 6 and 18 months of follow-up. Finally, most aripiprazole discontinuations were due to nonadherence (53.8%) and accumulated.

**Table 4. Intention-to-Treat Sample: Moderate or Severe Treatment-Emergent Adverse Effects That Occurred at a Rate of at Least 5% in Either Treatment Group**

|                     | Total (n=163) | Aripiprazole (n=66) | Quetiapine (n=45) | Ziprasidone (n=52) | χ² | P |
|---------------------|--------------|---------------------|------------------|--------------------|----|---|
| 6-weeks to 3 years |              |                     |                  |                    |    |   |
| Concentration difficulties | 29           | 17.8                | 19.7             | 19                 |    |   |
| Asthenia/increased fatigability | 74           | 45.4                | 39.4             | 53.3               |    |   |
| Sleepiness/sedation | 86           | 52.8                | 39.4             | 68.9               |    |   |
| Memory impairment | 7            | 4.3                 | 4.5              | 2.2                |    |   |
| Depression | 7            | 4.3                 | 4.5              | 2.2                |    |   |
| Restlessness | 7            | 4.3                 | 4.5              | 2.2                |    |   |
| Increased sleep duration | 52          | 31.9                | 21.2             | 42.2               |    |   |
| Rigidity | 9            | 5.5                 | 3.0              | 2.2                |    |   |
| Akinesia | 46           | 28.2                | 34.8             | 17.5               |    |   |
| Tremor | 14           | 8.6                 | 13.6             | 4.4                |    |   |
| Akathisia | 39           | 23.9                | 22.7             | 17.8               |    |   |
| Increased salivation | 29           | 17.8                | 16.7             | 20.0               |    |   |
| No salivation | 22           | 13.5                | 7.6              | 17.8               |    |   |
| Constipation | 19           | 11.7                | 10.6             | 15.6               |    |   |
| Miction impairment | 6            | 3.7                 | 6.1              | 2.2                |    |   |
| Vertigo | 7            | 4.3                 | 4.5              | 0.0                |    |   |
| Weight gain | 68           | 41.7                | 48.5             | 44.4               |    |   |
| Distimized sexual desire | 16           | 9.8                 | 9.1              | 13.3               |    |   |
| Orgasmic dysfunction | 6            | 3.7                 | 1.5              | 2                  |    |   |
| Amenorrhrea | 12           | 14.8                | 14.3             | 0.0                |    |   |
| Galarorrhea | 2            | 2.5                 | 0.0              | 0.0                |    |   |
| Ejaculatory dysfunction | 14           | 17.1                | 6.5              | 24.1               |    |   |
| Ejaculatory dysfunction | 13           | 15.9                | 6.5              | 20.7               |    |   |

**Effectiveness**

An impressive 80.69% of the initial sample completed follow-up. The overall treatment discontinuation rate (the cumulative percentage of discontinuation considering the 3 arms of the study) reached 81.7% by 3 years, which is in line with other medium and long-term (52 weeks or more) follow-up studies (Lieberman et al., 2005; McEvoy et al., 2007; Kahn et al., 2008; Mullins et al., 2008; Johnsen et al., 2010; Crespo-Facorro et al., 2012, 2014; San et al., 2012; Noguera et al., 2013). Interestingly, more than three-quarters of the patients who discontinued treatment did so during the first year of follow-up (76.4% by the end of year 1), in agreement with the studies mentioned previously. Such a high all-cause discontinuation rate represents a major issue, considering that adherence to maintenance treatment is the primary aim in FEP patients (San et al., 2012) after remission in order to prevent relapse. The all-cause treatment discontinuation rate in our sample was significantly greater in the quetiapine group, mainly due to nonefficacy or insufficient efficacy. Higher risk of all-cause treatment discontinuation in quetiapine patients had already been described during early phases of treatment (Ciudad et al., 2008; Crespo-Facorro et al., 2014). The median time to all-cause discontinuation in the quetiapine group was significantly shorter (60 days) than in the other 2 treatment groups: 452 days in the aripiprazole group and 251 days in the ziprasidone group. Despite no significant differences between aripiprazole and ziprasidone, there is a clear trend favoring aripiprazole, as can be observed on the K-M survival graph. Both aripiprazole and ziprasidone showed statistically significant superiority over quetiapine regarding median time to all-cause treatment discontinuation. We found that discontinuation because of nonefficacy or insufficient efficacy was higher in quetiapine (50.0%) compared with aripiprazole (15.38%) and ziprasidone (20.97%). Effectiveness studies using standard dosage ranges pointed out that quetiapine may be less effective than some other widely used SGAs (Ciudad et al., 2008; Asmal et al., 2013; Leucht et al., 2013; Tiihonen, 2016) and FGAs (Vanasse et al., 2016). Regarding the latter study, the authors also warned about a higher risk for health events related to quetiapine. Our results are consistent with the notion that most of the patients who start quetiapine stop taking it within a few weeks (Asmal et al., 2013). Inadequate and transient dopamine–2 receptor occupancy has been proposed as a possible mechanism underlying quetiapine lack of efficacy. On the other hand, its weak dopamine antagonism allows low maximal occupancy values and relatively little variability in occupancy values, suggesting that high doses of this antipsychotic are not likely to exceed thresholds of more than 80% occupancy, indicative for D2-receptor-mediated side effects (Lako et al., 2013). This supports the idea that higher doses may be tolerable and more efficient (McEvoy et al., 2007). We did not find significant differences between groups concerning treatment dosage adjusted by chlorpromazine equivalents prior to discontinuation due to nonefficacy or insufficient efficacy. The quetiapine group presented with a higher relative dosage compared with the other groups. According to other reports (Tiihonen et al., 2017), it is difficult to discern whether the poorer performance of quetiapine is due to the product itself or to nonoptimal dosage. It is of note that ziprasidone and aripiprazole all-cause discontinuations seem to occur later during treatment, likely due to the emergence of side effects (37.1% in ziprasidone group) and nonadherence (33.3% in aripiprazole group), respectively. Actually, most all-cause discontinuations in the ziprasidone sample due to secondary effects (65.2%) took place between 6 and 18 months of follow-up. Finally, most aripiprazole discontinuations were due to nonadherence (53.8%) and accumulated.
between the second and third years of follow-up. In this sense, aripiprazole seems to be the most effective and tolerable of the trio. The increase in discontinuations due to nonadherence observed during the last year of follow-up in this group might be explained by a natural decrease in the acceptability of treatment mediated by long-term exposure to treatment (Lieberman et al., 2005). Improvements in educational and other prophylactic measures like the use of long-acting injectable formulations (Jann and Penzak, 2018) may be of interest to deal with this preventable issue.

Efficacy

Our first-episode patients showed a decrease in total BPRS, SAPS, SANS, and CGI scores during the 3-year follow-up. The finding of no significant differences between treatment groups regarding the decrease in these clinical efficacy scales and responder rates agrees with previous reports (McEvoy et al., 2007; San et al., 2012). Remarkably, one-half of quetiapine discontinuations were due to nonefficacy or insufficient efficacy. The absence of differences observed in efficacy measures at 3 years may be attributable to the efficacy of the subsequent antipsychotic employed after initial treatment discontinuation. Differences in depressive symptom improvement between quetiapine and aripiprazole were observed, favoring the quetiapine group. Open-label trials had pointed out that quetiapine may be a useful agent in the management of depressive symptoms in individuals with psychosis (Samara et al., 2015). Quetiapine is acknowledged as a first-line treatment even in monotherapy in affective-psychoses (Lindström et al., 2017), but in several previous first-episode nonaffective psychoses studies, no significant differences between SGAs (including quetiapine) had been found in reducing depressive symptoms after mid-term follow-up (McEvoy et al., 2007; Kahn et al., 2008; Crespo-Facorro et al., 2014). No notable changes on negative symptoms were found with any of the 3 antipsychotics.

Side Effects and Concomitant Medications

The differences in the percentage of patients with treatment-emergent parkinsonism though, nonstatistically significant, may be of clinical interest. A higher percentage of extrapyramidal side effects and akathisia (Juncal-Ruiz et al., 2017) in aripiprazole and ziprasidone-treated individuals during the acute treatment of a first episode has been described. A higher incidence of akathisia early after aripiprazole and ziprasidone treatment was initiated has also been previously reported (Kerwin et al., 2007). This circumstance may partially explain that significantly more patients on aripiprazole needed benzodiazepines to relieve akathisia in our sample. In agreement with previous reports (Lee et al., 2011; Vázquez-Bourgon et al., 2018), no significant differences were found in the frequency of body weight increase between treatments, but a uniform trend to weight increase was appreciated with all of them. Intention-to-treat analysis revealed that 44.4% of the individuals on quetiapine, 48.5% on aripiprazole, and 30.8% on ziprasidone showed a rapid body weight gain (Table 4). Interestingly, the percentage of discontinuation due to severe or intolerable side effects in our study was relatively low (20.9 %) but significant in the case of ziprasidone, because it was its main cause of discontinuation (37.1%). Sleepiness/sedation was the most prevalent reported secondary effect for discontinuation in the case of ziprasidone (n=8; 34.7%) despite low doses prior to discontinuation due to secondary effects (58.5 mg [SD=34.3]).

Limitations and Strengths

Several limitations should be considered when interpreting our results. First, as a practical clinical trial, patients and observers (B.C.-F.) were not blinded to treatments in our study. The fact that the observers knew the medications prescribed may have involuntarily biased the outcomes. As a non-industry-funded study, the risk for systematic biased measuring study outcomes favoring any of the 3 SGAs is limited. Second, the mean doses of quetiapine used could be understood as somewhat low to treat first-episode individuals. However, controlled investigations have clearly confirmed that standard dosage range should be appropriate in everyday clinical practice (Johnsen and Jörgensen, 2008). Optimal doses of antipsychotics within the licensed range were chosen based on clinical efficacy and the presence of side effects and were adjusted according to the clinical situation of each patient. Treatment compliance measures were collected from self-report and close observers (family members and social assistants) but not from antipsychotic blood levels. This could have an impact in the accuracy of discontinuation measures due to noncompliance. On the other hand, this is one of the longest effectiveness studies regarding to follow-up (3 years). It was performed on a well-characterized and homogeneous sample, because most of patients (96%) were antipsychotic naïve prior to their inclusion.

Conclusions

Patients on quetiapine were more likely to discontinue treatment after an FEP globally and specifically at short and medium term due to nonefficacy or insufficient efficacy compared with aripiprazole and ziprasidone patients. Ziprasidone patients showed a greater tendency to discontinuation subordinated to persistent side effects in the mid-term. Finally, the majority of aripiprazole patients (the group with the longer time prior to discontinuation) who quit treatment did so in the last phase of follow-up (most of them reporting non-adherence). In summary, guaranteeing good adherence to effective antipsychotic treatment is one of the main challenges in the treatment of FEP individuals to prevent a malignant course of the disease. Establishing differences between SGAs regarding to risks and benefits of treatments and identifying different discontinuation patterns may contribute to optimize treatment selection after an FEP.

Funding

This work was supported by Plan Nacional de Drogas Research (2005-Orden sco/3246/2004); SENY Fundació (CI 2005-0308007); Fundación Marqués de Valdecilla (AP107/011); and Gerencia Regional de Salud de Castilla y León (INT/M/04/17). The study was carried out at the Hospital Marqués de Valdecilla, University of Cantabria, Santander, Spain. Unrestricted educational and research grants from AstraZeneca, Pfizer, Bristol-Myers Squibb, and Johnson & Johnson provided support for PAFIP activities. No pharmaceutical industry or institutional sponsors participated in the study design, data collection, analysis, or interpretation of the results.

Acknowledgments

This study was conducted as part of a clinical trial, “Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment
of First Episode Psychosis: 3-year Follow-up." (ClinicalTrials.gov identifier: NCT02526030). The authors thank the PAFIP research team, especially Gema Pardo and Obdulia Martínez, and all patients and family members who participated in the study. The authors are entirely responsible for the scientific content of the paper.

**Statement of Interest**

Dr José María Pelayo-Terán has received lecture honoraria and travel support from Janssen Johnson & Johnson, Lündbeck, Otsuka Pharmaceuticals, GlaxoSmithKline, and EliLilly. Prof. Benedicto Crespo-Facorro has received honoraria for consulting/ advisory boards from Otsuka Pharmaceuticals and lecture honoraria from Janssen Johnson & Johnson, Lündbeck, Roche, and Otsuka Pharmaceuticals. Dr Marcos Gómez-Revuelta has received lecture honoraria and travel support from Janssen Johnson & Johnson and Lündbeck.

Dr María Juncal-Ruiz has received lecture honoraria and travel support from Janssen Johnson & Johnson and Lündbeck. Dr Ana González-Pinto has received grants and served as consultant, advisor, or CME speaker for the following entities: Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Sanofi-Aventis, Alter, the Spanish Ministry of Science and Innovation, the Ministry of Science (Carlos III Institute), the Basque Government, and the Stanley Medical Research Institute. Dr Javier Vázquez-Bourgon and Víctor Ortiz-Garcia de la Foz report no additional financial support or other relationship relevant to the subject of this article.

**References**

Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Calgary depression scale. Br J Psychiatry 229:39–44.

Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, McGorry PD, Gleeson JP (2012) Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 139:116–128

Andreassen O (2016) The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.

Andreassen NC (1989) Scale for the Assessment of Negative Symptoms (SANS). Br J Psychiatry 155:53–58.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S (2013) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev doi: 10.1002/14651858.CD006625.pub3.

Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676.

Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W, Schizophrenia Patient Outcomes Research Team (PORT) (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36:71–93.

Caseiro O, Pérez-Iglesias R, Mata I, Martínez-García O, Pelayo-Terán JM, Tabares-Seisdedos R, Ortiz-García de la Foz V, Vázquez-Barquero JL, Crespo-Facorro B (2012) Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res 46:1099–1105.

Ciudad A, Haro JM, Alonso J, Boussofia M, Suárez D, Novick D, Gilaberte I (2008) The Schizophrenia Outpatient Health Outcomes (SCOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. Eur Psychiatry 23:1–7.

Crespo-Facorro B, Pérez-Iglesias R, Mata I, Martínez-García O, Ortiz V, Pelayo-Terán JM, Valdizán E, Vázquez-Barquero JL (2012) Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl) 219:225–233.

Crespo-Facorro B, Ortiz-García de la Foz V, Mata I, Ayasa-Arriola R, Suarez-Finilla P, Valdizán EM, Vázquez-Barquero JL, Pérez-Iglesias R (2013) Aripiprazole, ziprasidone and quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial. Schizophr Res 147:375–382.

Crespo-Facorro B, de la Foz VO, Mata I, Ayasa-Arriola R, Suarez-Finilla P, Valdizán EM, Martínez-García O, Pérez-Iglesias R (2014) Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year. Psychopharmacology (Berl) 231:357–366.

Emsley R, Chiliza B, Asmal I. (2013a) The evidence for illness progression after relapse in schizophrenia. Schizophr Res 148:117–121.

Emsley R, Chiliza B, Asmal I, Harvey BH (2013b) The nature of relapse in schizophrenia. BMC Psychiatry 13:50.

First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR axis I disorders research version, patient edition with psychotic screen (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute.

Gaebel W, Riesbeck M, Wölker W, Klimke A, Eckhoff M, von Wilsdsorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Köpcke W, Ohmann C, Möller HJ, German Study Group on First-Episode Schizophrenia (2011) Relapse prevention in first-episode schizophrenia—maintenance vs intermittent drug treatment with prodromebased early intervention: results of a randomized controlled trial within the german research network on schizophrenia. J Clin Psychiatry 72:205–218.

García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, González-Pinto A (2016) Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol 36:355–371.

Goff DC, Falkai P, Fleischhacker WW, Gurgis RR, Kahn RM, Uchida H, Zhao J, Lieberman JA (2017) The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry 174:840–849.

Gotzsche PC, Young AH, Crace J (2015) Does long term use of psychiatric drugs cause more harm than good? Bmj 350:h2435.

Guy W (1976) Ecdeu assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare publication ADM 76338.

Jann MW, Penzak SR (2018) Long-acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs 32:603.

Johnsen E, Jorgensen HA (2008) Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 8:1–14.

Johnsen E, Kroken RA, Wentzel-Larsen T, Jørgensen HA (2010) Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 10:46.

Juncal-Ruiz M, Ramirez-Bonilla M, Gomez-Arnau J, Ortiz-Garcia de la Foz V, Suarez-Bonilla P, Martinez-Garcia O, Neergaard KD, Tabares-Seisdedos R, Crespo-Facorro B (2017) Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised
study of antipsychotic treatment. Psychopharmacology (Berl) 234:2563–2570.
Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet JP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbée DE, EUFEST study group (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085–1097.
Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L’Italien G, McQuade RD, Beuzen JN (2007) A multicentre, randomised, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients schizophrenia trial of aripiprazole: (STAR) study. Eur Psychiatry 22:433–443.
Lee SY, Park MH, Patkar AA, Pae CU (2013) Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol 33:675–681.
Lally J, Ajnakina O, Stubbs B, Cullinane M, Murphy KC, Goughan F, Murray RM (2017) Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. Br J Psychiatry 211:350–358.
Lee SY, Park MH, Patkar AA, Pae CU (2011) A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuro-Psychopharmacol Biol Psychiatry 35:490–496.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379:2063–2071.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223.
Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup S (2008) Science and recovery in schizophrenia. Psychiatr Serv 59:487–496.
Lindström I, Lindström E, Nilsson M, Höistad M (2017) Maintenance therapy with second generation antipsychotics for bipolar disorder. A systematic review and meta-analysis. J Affect Disord 213:138–150.
Lingjaerde O, Ahlforss UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1–100.
Mayoral-van Son J, de la Foz VO, Martínez-García O, Moreno T, Parrilla-Escobar M, Valdizan EM, Crespo-Facorro B (2016) Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 77:492–500.
McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164:1050–1060.
Menezes NM, Arenovich T, Zipursky RB (2006) A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 36:1349.
Moncrieff J (2015) Antipsychotic maintenance treatment: time to rethink? Flos Med 12:e1001861.
Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD (2008) Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res 98:8–15.
Murray RM, Quattrone D, Natesan S, van Os J, Nordentoft M, Howes O, Di Forti M, Taylor D (2016) Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? Br J Psychiatry 209:361–365.
Nogueira A, Ballesta F, Baeza I, Arango C, de la Serna E, González-Pinto A, Parellada M, Graell M, Moreno C, Otero S, Castro-Fornieles J (2013) Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability. J Clin Psychopharmacol 33:463–471.
Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812.
Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, González-Blanch C, Martínez-García O, Pardo-García G, Rodríguez-Sánchez JM, Roiz-Santíañez R, Tordesillas-Gutiérrez D, Mata I, Vázquez-Barquero JL, Crespo-Facorro B (2008) Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in cantabria: insights from the clinical programme on early phases of psychosis. Early Interv Psychiatry 2:178–187.
Robinson DG, Woerner MG, Delman HM, Kane JM (2005) Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 31:705–722.
Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang JP, Lopez I, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, Lencz T, Correll CU, Kane JM, Malhotra AK (2015) A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull 41:1227–1236.
Samara MT, et al. (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172:617–629.
San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E (2012) One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Res 200:693–701.
Shrivastava A, Johnston M, Shah N, Bureau Y (2010) Redefining outcome measures in schizophrenia: integrating social and clinical parameters. Curr Opin Psychiatry 23:120–126.
Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19.
Tiihonen J (2016) Real-world effectiveness of antipsychotics. Acta Psychiatr Scand 134:371–373.
Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hotti F, Jedenius E, Enkusson D, Leval A, Serum J, Tanskanen A, Taipale H (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry 74:686–693.
van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645.
Vanesse A, Blais L, Courteau J, Cohen AA, Roberge P, Larouche A, Grignon S, Fleury MJ, Lesage A, Demers MF, Roy MA, Carrier JD, Delorme A (2016) Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment:
a real-world observational study. Acta Psychiatr Scand 134:374–384.
Vázquez-Bourgon J, Pérez-Iglesias R, Ortiz-García de la Foz V, Suárez Pinilla P, Díaz Martínez Á, Crespo-Facorro B (2018) Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naive patients with a first-episode of non-affective psychosis. Psychopharmacology (Berl) 235:245–255.
Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667.
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy. JAMA Psychiatry 70:913.
Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.
Zhu Y, Krause M, Huhn M, Rothe P, Schneider-Thoma J, Chaimani A, Li C, Davis JM, Leucht S (2017) Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. The Lancet Psychiatry 4:694–705.
Zipursky RB, Menezes NM, Streiner DL (2014) Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 152:408–414.